The Digester

A Nature paper shows a gene-editing strategy can reprogram T cells inside living mice to produce CAR T cells, offering a potential shortcut to current lab-based manufacturing while raising safety and translation challenges.

Nyberg et al. report an in vivo gene-editing method that generates CAR T cells directly in mice.
The technique bypasses current ex vivo manufacturing of CAR T therapies.
The study demonstrated activity in mouse models but has not been tested in humans.
Potential benefits include faster production, lower cost, and wider patient access if translated to people.
Significant safety questions remain, including off-target edits, immune reactions, and long-term effects.
Extensive preclinical validation and clinical trials will be required before human application.

Gene editing creates CAR T cells inside mice

Articles